GoodRx Now Offering 30 Common Heart Health Medications for Under $30

2024-02-15

AHA会议

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, the leading destination for prescription savings in the U.S., today announced it is offering 30 of the most common heart health medications for under $30 at more than 70,000 pharmacies nationwide.1 Cardiovascular disease is one of the most prominent conditions facing Americans, affecting nearly half of all U.S. adults. That’s why GoodRx is making it easier for all individuals, regardless of insurance status, to access savings on both generic and brand-name medications that mitigate the risk and impact of cardiovascular conditions such as coronary artery disease, high cholesterol, hypertension, and more.

'Improving access to affordable medications is the most important thing we can do to improve Americans\u2019 heart health. The second most important is ensuring access to helpful, accurate information'

By helping people afford their prescriptions, GoodRx is improving health outcomes and reducing the overall strain on the healthcare system. GoodRx’s recent report - The GoodRx Effect - estimates that GoodRx has directly contributed to the prevention of at least 140,000 emergency room visits and 110,000 hospitalizations for major adverse cardiovascular events like heart attack and stroke.

Save an average of 84% on common generic medications2

The following is a sample list of common generic medications used to treat cardiovascular disease that are available for under $30 on GoodRx.

MEDICATION

LOWEST PRICE3

AVG % SAVINGS4

ACE Inhibitors

Lisinopril (generic Prinivil and Zestril)

$9.29

67%

Enalapril (generic Epaned and Vasotec)

$15.54

75%

Beta Blockers

Carvedilol (generic Coreg)

$10.68

75%

Metoprolol ER (generic Toprol XL)

$11.15

74%

Propranolol (generic Inderal)

$10.96

71%

Calcium Channel Blockers

Amlodipine (generic Amvaz, Katerzia, and Norvasc)

$9.15

80%

Diltiazem ER (generic Cardizem CD)

$13.43

74%

Statins

Atorvastatin (generic Lipitor)

$10.10

83%

Pravastatin (generic Pravachol)

$14.53

74%

Rosuvastatin (generic Crestor)

$10.57

91%

Access exclusive discounts and savings on brand-name drugs

GoodRx offers incredible savings on brand-name medications that are often more costly and harder to obtain:

MEDICATION

SAVINGS*

Entresto

Pay as little as $10 for up to a 90-day supply

Jardiance

Pay as little as $10 per month

Lodoco

Pay as little as $30 for up to a 90-day supply

Ozempic Ozempic

Pay as little as $25 per month

Repatha

Pay as little as $5 per month

Soaanz

Exclusive discount to save over 70%

Toprol XL

Exclusive discount to save up to 51%

Xarelto

Pay as little as $10 per fill

*May require private or commercial insurance

Learn more about cardiovascular disease from trusted doctors, pharmacists and health experts

GoodRx Health is a go-to resource for understanding common heart conditions, risk factors, treatment options and associated savings. The GoodRx Heart Health Center provides credible, timely and actionable information to help people better manage their health. Each article is researched and written by a team of editorial experts, and clinical content is reviewed by a team of medical experts that includes physicians, pharmacists, and more.

“Improving access to affordable medications is the most important thing we can do to improve Americans’ heart health. The second most important is ensuring access to helpful, accurate information,” said Karla Robinson, MD, Medical Editor at GoodRx. “Knowledge is power, so we create easy-to-understand content that people can actually use so they are better equipped to minimize the risk of disease, find affordable medications, stick to their treatment plans, and ultimately improve their overall health and wellbeing.”

To find savings and trusted health information, download the GoodRx app or go to www.goodrx.com/hearthealth.

About GoodRx

GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save more than $65 billion and is one of the most downloaded medical apps over the past decade.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings; the benefits of our offerings to consumers, the U.S. healthcare system and GoodRx; and GoodRx’s plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, our reliance on a limited number of industry participants, the competitive nature of our industry, risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security and the important factors discussed in the section entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and our other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Prices are subject to change at any time without notice. Prices may vary at different pharmacies, and for different forms, dosages, and quantities.

Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023.

As of February 1, 2024.